Sight Sciences, Inc. (NASDAQ:SGHT) Given Average Recommendation of “Hold” by Brokerages

Sight Sciences, Inc. (NASDAQ:SGHT) has been assigned a consensus recommendation of “Hold” from the eight brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $5.1667.

Several brokerages have weighed in on SGHT. Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a research report on Thursday, November 20th. Piper Sandler raised their price objective on Sight Sciences from $4.00 to $5.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Wall Street Zen raised Sight Sciences from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a research report on Thursday, August 28th. Finally, Morgan Stanley lifted their price target on Sight Sciences from $4.00 to $6.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th.

Insider Buying and Selling at Sight Sciences

In related news, insider Jeremy B. Hayden sold 3,150 shares of Sight Sciences stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $8.01, for a total transaction of $25,231.50. Following the completion of the transaction, the insider directly owned 256,590 shares in the company, valued at $2,055,285.90. The trade was a 1.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Brenton Taylor sold 14,418 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $7.06, for a total value of $101,791.08. Following the sale, the executive vice president owned 170,831 shares in the company, valued at approximately $1,206,066.86. This trade represents a 7.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 58,364 shares of company stock valued at $262,195 over the last quarter. Corporate insiders own 28.90% of the company’s stock.

Institutional Trading of Sight Sciences

Several institutional investors and hedge funds have recently made changes to their positions in the stock. KCK LTD. purchased a new stake in Sight Sciences during the 2nd quarter worth about $18,069,000. Long Focus Capital Management LLC grew its holdings in shares of Sight Sciences by 1.3% during the third quarter. Long Focus Capital Management LLC now owns 3,193,305 shares of the company’s stock worth $10,985,000 after buying an additional 41,797 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Sight Sciences by 5.7% in the third quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company’s stock valued at $6,559,000 after buying an additional 102,609 shares during the last quarter. Americana Partners LLC raised its position in shares of Sight Sciences by 42.4% in the third quarter. Americana Partners LLC now owns 1,229,819 shares of the company’s stock valued at $4,231,000 after buying an additional 365,901 shares during the last quarter. Finally, B Group Inc. lifted its stake in shares of Sight Sciences by 11.6% during the second quarter. B Group Inc. now owns 930,000 shares of the company’s stock valued at $3,841,000 after buying an additional 96,400 shares during the period. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Sight Sciences Trading Up 8.1%

NASDAQ:SGHT opened at $8.10 on Friday. Sight Sciences has a 1 year low of $2.03 and a 1 year high of $8.23. The company has a debt-to-equity ratio of 0.62, a quick ratio of 8.93 and a current ratio of 9.60. The stock has a fifty day moving average price of $4.87 and a two-hundred day moving average price of $4.18. The stock has a market capitalization of $428.25 million, a price-to-earnings ratio of -9.00 and a beta of 2.47.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Wednesday, September 8th. The company reported ($0.81) EPS for the quarter. The company had revenue of $12.54 million for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%. As a group, sell-side analysts anticipate that Sight Sciences will post -0.99 earnings per share for the current fiscal year.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.